Stocktoria
GLOBUS MEDICAL INC GMED
GLOBUS MEDICAL INC (GMED) earns a Piotroski F-score of 7/9 (strong financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $2.9B at a 18.3% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.44 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-08-07 | Wells Fargo | Overweight (main) |
| 2026-07-28 | UBS | Neutral (init) |
| 2026-07-16 | Truist Securities | Buy (main) |
| 2026-07-13 | RBC Capital | Outperform (main) |
| 2026-07-09 | BMO Capital | Outperform (init) |
| 2026-07-08 | Stifel | Hold (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Forward estimates · earnings calendar →
Consensus analyst estimates and scheduled dates — forward-looking, may change.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 7/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.307 |
| Retained earnings / assets | 0.262 |
| EBIT / assets | 0.09 |
| Equity / liabilities | 6.269 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| GMED | GLOBUS MEDICAL INC | 7/9 | 10.06 | 21.8 | +16.7% |
| WST | WEST PHARMACEUTICAL SERVICES INC | 7/9 | 9.34 | 47.2 | +6.3% |
| MMED | MiniMed Group, Inc. | 3/9 | 4.28 | — | +14.3% |
| PODD | INSULET CORP | 6/9 | 4.78 | 44.4 | +30.7% |
| ICUI | ICU MEDICAL INC/DE | 6/9 | 2.9 | — | -6.3% |
| TFX | TELEFLEX INC | 5/9 | 3.56 | — | +17.2% |
| IART | INTEGRA LIFESCIENCES HOLDINGS CORP | 5/9 | 1.17 | — | +1.5% |
About GLOBUS MEDICAL INC
Globus Medical, Inc. develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products comprising traditional fusion implants, such as pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices; treatment options for motion preservation technologies consisting of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and biologic solutions, such as allografts and synthetic alternatives. It also provides orthopedic trauma solutions, including limb reconstruction, fracture plating, intramedullary nailing, external fixation, and compression screw technologies; hip and knee arthroplasty solutions, including modular cement and cementless hip stems, acetabular cups, femoral heads, highly cross-linked liners, partial knee systems, cruciate retaining, posterior stabilized, and revision options; spinal cord stimulation services; and neuromonitoring services, which provide onsite and remote monitoring of the neurological systems. In addition, the company offers ExcelsiusGPS platform, a robotic guidance and navigation system for minimally invasive and open procedures; Surgimap, a surgical planning software platform; Excelsius3D, a platform combined with ExcelsiusGPS that provides an intraoperative and image-guided robotic navigation solution; ExcelsiusHub, which provides real-time patient array monitoring, tissue sparing drills, and registration flexibility; and ExcelsiusFlex, a total knee arthroplasty robotic solution. Further, it distributes human cells, tissues, and cellular and tissue-based products. The company sells its products through direct and distributor sales representatives; and independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.
FAQ
Is GMED financially healthy?
GLOBUS MEDICAL INC's Piotroski F-score is 7/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does GMED pay a dividend?
No, GLOBUS MEDICAL INC does not currently pay a dividend.
How profitable is GMED?
In FY2025, GLOBUS MEDICAL INC had a net margin of 18.3% and a return on equity of 11.8%.
Is GMED overvalued or undervalued?
GLOBUS MEDICAL INC trades at about 21.9× trailing earnings — below its 10-year norm (10-year range 23.1×–123.6×, median 41.9×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for GMED?
The average Wall-Street price target for GLOBUS MEDICAL INC is $103.23, about 20.5% above the recent price, from 13 analysts (consensus: buy).
Is GMED a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on GLOBUS MEDICAL INC: a Piotroski F-score of 7/9, an Altman Z″ in the safe zone, a P/E of about 21.8×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.